Independent Director 2025 Annual Performance Report
I, as an independent director of Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), during my term of office in 2025, have strictly complied with the provisions of the Company Law, the Securities Law, the Corporate Governance Guidelines for Listed Companies, the Administrative Measures for Independent Directors of Listed Companies, and other relevant laws and regulations, as well as the Company's Articles of Association and the Independent Director Work System. I have faithfully, diligently, and conscientiously performed my duties as an independent director, actively leveraging my independence and professionalism to safeguard the interests of the Company and all shareholders, especially small and medium shareholders.
Here is my performance report for 2025:
I. Basic Information
I, Wang Fuqing, born in 1963, am a Chinese national with no overseas residency and hold a postgraduate degree. I previously served as a pharmacist at the Binzhou Regional Drug Inspection Institute in Shandong Province and held positions in the former Ministry of Commerce and the former State Administration of Domestic Trade. I am currently the Vice President of the China Pharmaceutical Enterprise Management Association. I have served as an independent director of the Company since May 2024.
II. Annual Performance
(I) Attendance at Board Meetings and Shareholders' Meetings
As an independent director, during my term of office, I have attended all 5 board meetings organized by the Company in accordance with regulations and on time. I have diligently reviewed a total of 67 proposals at the board meetings and have not authorized any other independent director to attend board meetings on my behalf. I believe that the procedures for convening and holding the Company's board meetings are legal and compliant, that major matters have undergone legal and effective decision-making and approval procedures, and that the resolutions passed by the meetings have not harmed the legitimate rights and interests of all shareholders, especially small and medium shareholders. I have reviewed proposals with an objective and cautious attitude, exercised my voting rights prudently, and voted in favor of all proposals and other matters of the Company during my term of office, without raising any objections, opposing votes, or abstentions. The specific details of my attendance at board meetings and shareholders' meetings during my term of office are as follows: